12-GBM-05-CT(CDX 110-04) Rindopepimut+Temozolomide in Newly Diagnosed, Surgically Resected, EGFRVIII-positive Glioblastoma

Grants and Contracts Details

StatusFinished
Effective start/end date8/24/12 → 7/31/17

Funding

  • Celldex Therapeutics Incorporated: $114,970.00